Inhibition of AKT3 in an early stage of breast cancer without metastases or at the beginning of the metastatic cascade seems not expedient, whereas in patients with already developed bone metastases, inhibition of AKT3 could be advantageous. The gene discussed is AKT3; the disease is breast cancer.